The fact is that it works really well in some people, but not in all. The report and those facts are widely known now. Researchers are trying to find out why in some there is no impact and it others it increases survival. Bottom line this is the nature of these new therapies. It started with an amazing drug idea called Irressa for lung cancer - it was financial flop, but in 10% of the people that got it, it worked 100% of the time. There is so much we do not know about this new field of genomics, proteomics, and molecular targeted therapies. This really is the future, but we are still in the learning curve. Not a bad drug, but like all drugs, it has its limitations, and no drug - not even ones held up as paradigm changing, like the polio vaccine which eradicated polio from our country and saved millions of lives, helped everyone, and some people it even hurt. But overall it was an amazing breakthrough vaccine.

As it turns out Martha should not have sold her stock, ImClone was bought buy a bigger pharma firm Pfizer, and BMS and another big firm in Europe came in as marketing partners for Erbitux, and she would have made a lot of money.

At the end of the day, no drug is 100% safe in 100% of people it is given to, not even aspirin�...